Prognostic significance of third-line treatment for patients with metastatic castration-resistant prostate cancer: comparative assessments between cabazitaxel and other agents.
Int J Clin Oncol
; 26(9): 1745-1751, 2021 Sep.
Article
em En
| MEDLINE
| ID: mdl-34255227
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article